English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBusinessEarningsAlembic Pharma Q4 net up 115% at Rs 43.6 cr, stock rises 2%

    Alembic Pharma Q4 net up 115% at Rs 43.6 cr, stock rises 2%

    Healthcare firm Alembic Pharma's fourth quarter (January-March) net profit grew 115 percent year-on-year to Rs 43.6 crore, sending shares to 52-week high of Rs 122 on Thursday.

    May 02, 2013 / 15:20 IST
       
       
      26 Aug, 2025 12:21
      Volume
      Todays L/H
      More

      Healthcare firm Alembic Pharma's fourth quarter (January-March) net profit grew 115 percent year-on-year to Rs 43.6 crore, sending shares to 52-week high of Rs 122 on Thursday.


      Consolidated net sales rose by 10 percent to Rs 376.6 crore from Rs 342.3 crore Y-o-Y.


      Its domestic formulations' sales jumped 12 percent Y-o-Y to Rs 207.52 crore while international generics sales grew by 54 percent to Rs 77.66 crore.

      Also Read - Aurobindo Pharma receives USFDA nod for Quinapril tablets


      In the three-month period, the company launched Desvenlafaxine Base extended release tablets in the US. Company also made its new formulations facility partially operational during the quarter.


      At 14:55 hours IST, the stock gained 1.88 percent to Rs 116.30 amid hefty volumes on Bombay Stock Exchange.

      first published: May 2, 2013 03:20 pm

      Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

      Subscribe to Tech Newsletters

      • On Saturdays

        Find the best of Al News in one place, specially curated for you every weekend.

      • Daily-Weekdays

        Stay on top of the latest tech trends and biggest startup news.

      Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347